Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 41 Lung Neoplasms 11 Lymphoma, Large-Cell, Anaplastic 8 Neoplasm Metastasis 7 Multiple Myeloma 6 Lymphoma 6 Neoplasms 5 Colorectal Neoplasms 4 Adenocarcinoma 4 Uveal Melanoma 3 Neuroblastoma 3 Melanoma 3 Hematologic Neoplasms 3 Granuloma, Plasma Cell 3 Carcinoma, Renal Cell 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Glioma 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × Crizotinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡